Mondorf, Yvonne and Mikuteit, Marie and Ivanyi, Philipp and Stoehr, Christine and Herrmann, Edwin and Polifka, Iris and Agaimy, Abbas and Trojan, Lutz and Stroebel, Philipp and Becker, Frank and Wuelfing, Christian and Barth, Peter and Stoeckle, Michael and Staehler, Michael and Stief, Christian G. and Haferkamp, Axel and Hohenfellner, Markus and Macher-Goeppinger, Stephan and Wullich, Bernd and Noldus, Joachim and Brenner, Walburgis and Roos, Frederik C. and Walter, Bernhard and Otto, Wolfgang and Burger, Maximilian and Schrader, Andres Jan and Hartmann, Arndt and Steffens, Sandra and Erlmeier, Franziska (2022) The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. UROLOGIA INTERNATIONALIS, 106 (11). pp. 1168-1176. ISSN 0042-1138, 1423-0399
Full text not available from this repository. (Request a copy)Abstract
Introduction: Programmed death-1 ligand (PD-L1) has been often studied in different types of renal-cell carcinoma (RCC). For example, in clear-cell renal carcinoma it is well established that programmed death-1 receptor and PD-L1 are important prognostic markers. In contrast, the role of programmed death-2 ligand (PD-L2) as prognostic marker remains unclear. The aim of this study was to evaluate if PD-L2 expression could play a role as a prognostic marker for papillary RCC (pRCC). Methods: The patients' sample collection was a joint collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of PD-L2 was determined by immunohistochemistry. In total, PD-L2 staining was evaluable in 185 of 240 type 1 and 99 of 128 type 2 pRCC cases. Results: PD-L2 staining was positive in 67 (36.2%) of type 1 and in 31 (31.3%) of type 2 pRCC specimens. The prevalence of PD-L2+ cells was significantly higher in high-grade type 1 tumors (p = 0.019) and in type 2 patients with metastasis (p = 0.002). Kaplan-Meier analysis disclosed significant differences in 5-year overall survival (OS) for patients with PD-L2- compared to PD-L2+ in pRCC type 1 of 88.4% compared to 73.6% (p = 0.039) and type 2 of 78.8% compared to 39.1% % (p < 0.001). However, multivariate analysis did not identify the presence of PD-L2+ cells neither in type 1 nor type 2 pRCC as an independent predictor of poor OS. Discussion/Conclusion: PD-L2 expression did not qualify as an independent prognostic marker in pRCC. Future studies will have to determine whether anti-PD-L2-targeted treatment may play a role in pRCC and expression can potentially serve as a predictive marker for these therapeutic approaches.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | EXPRESSION; SURVIVAL; ANTIBODY; SAFETY; Programmed death-2 ligand; Papillary renal-cell carcinoma; Prognosis; Survival |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 07 Sep 2023 12:54 |
| Last Modified: | 07 Sep 2023 12:54 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58578 |
Actions (login required)
 |
View Item |
